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PIH18  
COSTS OF GLOBAL ENDOMETRIAL ABLATION (GEA) FOR TREATMENT OF 
HEAVY MENSTRUAL BLEEDING (MENORRHAGIA): ASSIMILATION AND 
COMPARISON OF RESULTS FROM PUBLISHED COST-EFFECTIVENESS  
MODELING STUDIES  
Miller JD 
Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: Most cost-effectiveness modeling studies of global endometrial 
ablation (GEA) for treatment of heavy menstrual bleeding (menorrhagia) are from 
a UK perspective. Costs and cost-effectiveness information about GEA from a US 
perspective are lacking. Study objectives were: 1) identify/review all cost-
effectiveness modeling studies of GEA; 2) assimilate GEA costs across these 
studies at current levels (2012 US dollars) to proxy a US market perspective; and 
3) perform statistical summarizations of the data. METHODS: All published 
literature and health technology assessments of menorrhagia treatment cost-
effectiveness published 2004-2012 were reviewed; studies with GEA as a 
comparator were selected for inclusion. GEA cost data were abstracted and 
converted to US dollars using purchasing power parity indices (PPPI) and 
adjusted to 2012 levels using the US consumer price index (CPI). Statistical 
summarizations (minimum, maximum, mean, median) were performed for 
studies in their respective 1-, 2-, 5-, and 10-year analysis scenarios. RESULTS: 
From a total of eight cost-effectiveness modeling studies, 14 GEA cost data values 
were abstracted. All values pertained to either microwave endometrial ablation 
(MEA) or thermal balloon endometrial ablation (TBEA), or a composite weighted 
average of the two techniques. No studies reported costs associated with 
cryoablation, bipolar radiofrequency ablation, or hydrothermal ablation (HTA). 
Adjusted GEA costs from two 1-year analyses ranged from $1,011 to $1,329 
(mean/median $1,170). Costs from a single 2-year analysis were $2140. Costs 
from four 5-year analyses ranged from $2700 to $3748 (mean $3359, median 
$3493). Costs from seven 10-year analyses ranged from $2495 to $4549 (mean 
$3264, median $3119). CONCLUSIONS: There was a large degree of heterogeneity 
in scope and comprehensiveness of cost accounting in the GEA cost analyses 
summarized here. Although only proxy estimates of GEA costs in the US, results 
of this study serve as useful benchmarks for cost evaluations of GEA in the 
dramatically changing menorrhagia-treatment market.  
 
PIH19  
A CASE-CONTROLLED, RETROSPECTIVE ANALYSES OF PRETERM LABOR AND 
PRETERM BIRTH IN PREMIER'S PERSPECTIVE HOSPITAL DATABASE (2003-2010)  
Black L1, Carroll C2 
1GlaxoSmithKline, Research Triangle Park, NC, USA, 2GlaxoSmithKline, RTP, NC, USA  
OBJECTIVES: To profile a cohort of women and infants who received a diagnosis 
of preterm labor (PTL)/preterm birth (PTB), and to compare the health care 
burden of these cohorts to term deliveries/infants. METHODS: Retrospective 
analysis of Premier Perspective Hospital Database. Sample populations of 
women who delivered and infants who were born (2003-2010), were identified 
and a case controlled analysis was conducted comparing PTL-deliveries/PTB-
infants with term deliveries/infants. Secondary outcomes included summaries of 
resource utilization and costs. Maternal cases and controls and infant cases and 
controls were matched 1 to 1, based on year of delivery/birth, mother’s delivery 
age (mothers only), race, provider area, rural/urban, and payor type. RESULTS: A 
total of 432,808 women had a diagnosis code of PTL with delivery, the fewest 
(9.4%) in 2003 and the most (15.5%) in 2009. Tocolytic drug use was recorded in 
37% of cases. Cases with delivery had a mean length of stay (LOS) of 3.06 days 
(controls = 2.25 days) and mean per patient costs of $8032 (controls = $5311). 
There were 314,577 case infants with either a gestational age (GA) ICD9 code or a 
birth weight ICD9 code. Total mean cost per case with in-hospital deaths 
included was $70,074 (controls = $4,505). More deaths occurred in the case cohort 
versus the control cohort (6941 vs. 121, respectively). The case mean hospital LOS 
was 14.27 days (controls = 2.39 days). The extremely premature (<25-26 wks) 
made up approximately 4% of PTBs and 22% of total hospital costs versus late 
preterm (33-36 wks) made up approximately 69% of PTBs and 30% of total 
hospital costs. CONCLUSIONS: The most extreme premature infants accounted 
for 22% of the total preterm hospital costs. Being able to prolong the pregnancy 
across the entire GA range, but particularly in the very preterm, has the potential 
for substantial cost savings.  
 
PIH20  
HEALTH-ECONOMICS ANALYSIS OF DISEASES RELATED TO THE 
DISTURBANCES OF ADAPTATION: A COST OF ILLNESS STUDY  
Boncz I, Kovacs GL, Ertl T, Ágoston I, Molics B, Bódis J 
University of Pécs, Pécs, Hungary  
OBJECTIVES: The aim of our study is to perform the health-economics analysis 
of diseases related to disturbances of adaptation by a cost of illness study in 
Hungary. METHODS: Data were derived from the financial dataset of the 
National Health Insurance Fund Administration (OEP) covering the year 2009. 
Four disease were included into the analysis: polycystic ovary syndrome (E2820), 
retinopathy of prematurity (H3510), a hyperstimulation of ovaries (N9810) and 
respiratory distress syndrome of newborn (P2200). RESULTS: The annual health 
insurance cost of diseases were the following: polycystic ovary syndrome: 78.9 
million Hungarian Forint (HUF) or EUR€281,160, retinopathy of prematurity: HUF 
41.3 million (EUR€147,090), hyperstimulation of ovaries: HUF 8.7 million 
(EUR€30,839) and respiratory distress syndrome of newborn: HUF 1.562 million 
(EUR€5,567,336). We found by far the highest annual per capita health insurance 
expenditure in respiratory distress syndrome of newborn (HUF 1.43 million or 
EUR€5098/patient/year). Hyperstimulation of ovaries (HUF 58,073 or 
EUR€207/patient/year), retinopathy of prematurity (HUF 19,513 or EUR€70/ 
patient/year) and polycystic ovary syndrome (HUF 7679 or EUR€27/patient/year) 
showed significantly lower annual per capita health insurance expenditure. 
CONCLUSIONS: The annual health insurance expenditures of diseases related to 
the disturbances of adaptation are high (HUF 1689 million or EUR€6.02 million) 
and among that diseases respiratory distress syndrome of newborn has the 
highest burden of disease.  
 
PIH21  
MEDICAL, DRUG, AND WORK-LOSS COSTS OF VENOUS LEG ULCERS  
Rice JB1, Desai U1, Cummings AK1, Birnbaum HG1, Skornicki M2, Parsons N2 
1Analysis Group, Inc., Boston, MA, USA, 2Organogenesis Inc., Canton, MA, USA  
OBJECTIVES: Estimate annual per-patient medical, drug, and work-loss costs of 
venous leg ulcers (VLU) using de-identified administrative claims data. 
METHODS: Beneficiaries with (VLU) and without VLU (controls) were identified 
using two databases: ages 65+ from a 5% random sample of Medicare 
beneficiaries (Standard Analytical Files, 2007-2010; VLU N=60,840, controls N= 
699,506) and ages 18-64 from a privately-insured population (OptumInsight, 
2007-2011; VLU N=26,096, controls N= 1,300,455). Patients were required to be 
continuously eligible during the 12 months before (baseline) and 12 months after 
(study period) the index date (i.e., the date of the most recent VLU diagnosis 
following 12 months without VLU diagnoses (VLU group); or the date of a random 
medical claim (controls)). VLU patients were matched to controls using 
propensity scores to account for baseline differences in demographics, 
comorbidities, resource utilization, and costs. Medical costs incurred during the 
study period were calculated for both Medicare and privately-insured patients. 
Because drug and work-loss (absenteeism or disability) data were unavailable for 
Medicare patients, these costs were estimated for the privately-insured sample 
only. Differences in study period costs were compared using Wilcoxon signed-
rank tests. RESULTS: Data for 22,900 matched pairs of privately-insured and 
58,616 matched pairs of Medicare patients were analyzed. VLU patients incurred 
incremental medical costs of $6,080 in Medicare ($18,246 vs. $12,165), with 
privately-insured VLU patients having excess medical costs of $7,012 ($13,552 vs. 
$6,540). Among the privately-insured, 89% of the cost differential was 
attributable to excess inpatient and outpatient/physician office costs. For 
Medicare, the excess costs were approximately equally distributed among all 
places of services. Among the privately-insured, the VLU patients and controls 
incurred similar drug costs, however, VLU patients had $454 more in work-loss 
costs (absenteeism: +$367, disability: +$87). (Comparisons significant at 
p<0.0001). CONCLUSIONS: With VLU incidence estimates of 2.5 million, these 
findings suggest an annual payer burden up to $18 billion.  
 
PIH22  
COMPARATIVE DIRECT AND INDIRECT COSTS OF MENORRHAGIA TREATMENT 
WITH GLOBAL ENDOMETRIAL ABLATION OR HYSTERECTOMY  
Bonafede MM, Miller J, Meyer NM, Lenhart GM 
Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To describe the treatment patterns, health care utilization, medical, 
and productivity costs among commercially insured women initiating 
menorrhagia treatment with global endometrial ablation (GEA) or hysterectomy. 
METHODS: Women aged 30-55 years with diagnosed menorrhagia who initiated 
menorrhagia treatment with GEA or hysterectomy (index event) during 2006-
2010 were identified in the Truven Health MarketScan® Commercial Claims and 
Encounters Database. One-year of continuous enrollment pre- and post-index 
event was required to evaluate baseline characteristics and outcome measures. 
Health care utilization and costs (2011 USD) were assessed in the year following 
treatment initiation. Workplace absenteeism and short-term disability (STD) 
costs were reported for a subset of patients. RESULTS: Two-thirds (66.3%) of the 
61,602 study patients initiated menorrhagia treatment with GEA compared to 
hysterectomy (33.7%). Average age was similar between treatments (43.2 years), 
as was the baseline Deyo-Charlson Comorbidity score (0.17), and use of 
prescription non-steroidal anti-inflammatory drugs (29%). The majority (96%) of 
GEA procedures occurred in an outpatient setting compared to 18% of 
hysterectomy procedures. Treatment-related complications were more common 
for hysterectomy (36%) than for GEA (15%, p<0.001). Treatment initiation and 30-
day followup costs were higher for hysterectomy ($12,147) than for GEA ($5,837, 
p<0.001), as were gynecologic-related costs for remainder of the year ($284 vs. 
$147, p<0.001). Absenteeism costs in the year following treatment initiation were 
higher for hysterectomy ($7543) than for GEA ($5621, p<0.001). Hysterectomy 
patients were four times more likely to have a STD claim than GEA patients (84% 
vs. 21%, p<0.001) with similar costs per-claim ($6802 vs. $6472, p=0.29), which 
resulted in higher per-patient STD costs across all patients ($5744 vs. $1361, 
p<0.001). CONCLUSIONS: Hysterectomy cost was nearly two times higher than 
GEA for menorrhagia treatment. Lost productivity represented a significant 
portion of this cost difference as hysterectomy patients were substantially more 
likely to have a STD claim and had higher costs per claim.  
 
PIH23  
COST-EFFECTIVENESS OF 13-VALENT VERSUS 23-VALENT PNEUMOCOCCAL 
POLYSACCHARIDE VACCINE AND NO VACCINATION IN THE CZECH NATIONAL 
VACCINATION PROGRAM  
Zigmond J1, Tichopad A1, Kolek V2, Roberts CS3, Hajek P4 
1CEEOR s.r.o., Prague, Czech Republic, 2Olomouc University Hospital, Olomouc, Czech Republic, 
3Pfizer, New York, NY, USA, 4Pfizer s r.o., Prague, Czech Republic  
OBJECTIVES: Czech guidelines recommend 23-valent pneumococcal 
polysaccharide vaccination (PPSV23) for people living in homes for the elderly, 
long-term hospitals, homes for the disabled and special-regime homes (the  
last two were excluded for lack of valid data, assuming that wouldn’t influence 
results since they make only a negligible part of vaccinated people). A 13-valent 
pneumococcal conjugate vaccine (PCV13) has had significant public-health 
